GlobeNewswire Inc | Dec 28, 2020 04:05PM EST

December 28, 2020

CARLSBAD, Calif., Dec. 28, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (GenMark or the Company), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in two upcoming investor conferences.

GenMarks management is scheduled to present at the 39th Annual J.P. Morgan Healthcare Conference in a virtual setting on Tuesday, January 12th, 2021 at 5:20 p.m. ET. Interested parties can access the live and archived webcast at ir.genmarkdx.com.

GenMarks management is also scheduled to present at the 23rd Annual Needham Growth Conference in a virtual setting on Thursday, January 14, 2021 at 5:00 p.m. ET. Interested parties can access the live and archived webcast at ir.genmarkdx.com.

ABOUT GENMARK

GenMark is a leading provider of multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics, and reduce the total cost-of-care. Utilizing GenMark's proprietary eSensordetection technology, GenMark's eSensor XT-8and ePlexsystems are designed to support a broad range of molecular diagnostic tests with compact, easy-to-use workstations and self-contained, disposable test cartridges. GenMarks ePlex:The True Sample-to-Answer Solution is designed to optimize laboratory efficiency and address a broad range of infectious disease testing needs, including respiratory, bloodstream, and gastrointestinal infections. For more information, visitwww.genmarkdx.com.

Investor Relations ContactLeigh Salvo(415) 937-5404ir@genmarkdx.com